Safety of Attenuated Smallpox Vaccine LC16m8 in Immunodeficient Mice | Zendy

Hiroyuki Yokote | Zendy; Yasuhiko Shinmura | Zendy; Tomomi Kanehara | Zendy; Shinichi Maruno | Zendy; Masahiko Kuranaga | Zendy; Hajime Matsui | Zendy; So Hashizume | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Safety of Attenuated Smallpox Vaccine LC16m8 in Immunodeficient Mice

Author(s) -

Hiroyuki Yokote,

Yasuhiko Shinmura,

Tomomi Kanehara,

Shinichi Maruno,

Masahiko Kuranaga,

Hajime Matsui,

So Hashizume

Publication year - 2014

Publication title -

clinical and vaccine immunology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.649

H-Index - 77

eISSN - 1556-6811

pISSN - 1556-679X

DOI - 10.1128/cvi.00199-14

Subject(s) - smallpox , smallpox vaccine , virology , virulence , attenuated vaccine , stockpile , immunology , anthrax vaccines , medicine , vaccination , biology , vaccinia , immunization , immune system , gene , dna vaccination , genetics , political science , recombinant dna , law

Freeze-dried live attenuated smallpox vaccine LC16m8 prepared in cell culture has been the sole smallpox vaccine licensed in Japan since 1975 and was recently recommended as a WHO stockpile vaccine. We evaluated the safety of recently remanufactured lots of LC16m8 using a series of immunodeficient mouse models. These models included suckling mice, severe combined immunodeficiency disease (SCID) mice, and wild-type mice treated with cyclosporine. LC16m8 showed extremely low virulence in each of the three mouse models compared with that of its parental strains, Lister and LC16mO. These results provide further evidence that LC16m8 is one of the safest replication-competent smallpox vaccines in the world and may be considered for use in immunodeficient patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research